Search results
Results from the WOW.Com Content Network
The VOICE trial is testing 1% tenofovir vaginal gel in a once-daily formulation. It is not known at this time if VOICE will be considered a confirmatory trial for CAPRISA 004, which used a different dosing strategy. [32] Products known as Pre-Exposure Prophylaxis, or PrEP, are also being tested at various stages of the development process.
PVP-I is approved for treatment of bacterial vaginosis as a vaginal gel. [18] [19] [20] Brand names include Astodrimer Sodium or Astrodimer 1% Vaginal Gel, Betadine BV, Betafem BV, Viraleze, and VivaGel, among others. [18] [19] [20] Vaginal suppositories are also available and used. [21]
The trial involved 222 men, ages 18 to 50, who applied 5 milliliters of the gel (about a teaspoon) to each of their shoulder blades once per day. The second part of the two-part trial is still ...
Administering a vaginal tablet without an applicator. Intravaginal administration is a route of administration where the substance is applied inside the vagina . Pharmacologically , it has the potential advantage to result in effects primarily in the vagina or nearby structures (such as the vaginal portion of cervix ) with limited systemic ...
Whether you're a longtime Costco shopper or are simply curious about the types of brands you can find at the international retailer, below are 15 best-selling beauty products at Costco that have ...
The ideal vaginal microbicide would have the following characteristics: provide protection against infection not require application at the time of intercourse not harm the natural tissue [3] As of 2009, not harming natural tissue was the most troublesome aspect of development.
Starbucks Iced Coffee (2-Count) Price: $11.59 On its own, a 48-fluid ounce bottle of Starbucks iced coffee in the medium roast blend can cost as much $7 or more at the typical supermarket ...
Nonoxynol-9 is a common ingredient of most vaginal and anal lubricants due to its spermicidal properties. A 2004 study found that over a six-month period, the typical-use failure rates for five nonoxynol-9 vaginal contraceptives (film, suppository, and gels at three different concentrations) ranged from 10% to 20%.